Clinical Need

Cataracts are a loss of vision due to lens clouding.

If left untreated, cataracts can lead to blindness.

Current treatment options have limitations with visual side effects: glares, halos and artifacts.

Currently no solution mimics the natural ability of the eye to provide a full range of vision, from distance to near.

Solution

Atia Vision Modular Presbyopia Correcting Intraocular Lens (IOL)

Designed for true accommodation, aiming to restore the full range of vision

See How It Works

Watch the video to learn more about the Atia Vision Modular Presbyopia Correcting IOL

Watch the Video >

Company

Atia Vision is a portfolio company of Shifamed, LLC, a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.

The team at Atia Vision is committed to improving patient outcomes by developing a safe and controllable presbyopia correcting IOL that aims to restore the full range of functional vision in cataract patients, the largest segment of the ophthalmology market.3

Management Team

Mariam Maghribi

President & CEO

David Voris

Chief Financial Officer

John Scholl

Vice President, Product Development

Debbie White

Senior Vice President, Human Resources

Robert Edesess

Vice President, Intellectual Property

Melissa Guerrero

Director of Quality Assurance

Helene Lamielle

Clinical & Regulatory Consultant

Board of Directors

Amr Salahieh

Atia Vision Chairman, President & CEO, Shifamed

Mariam Maghribi

President & CEO,
Atia Vision

Claudio Argento

Chief Technology Officer, Atia Vision

Bihua Chen

Founder & CEO, Cormorant Asset Management

Casey Gordon

Head of Private Investments,
The Capital Partnership

Henry Chen

Founder & Managing Partner, Delos Capital

Interested in joining the Atia Vision team?

Click here to see open positions with Atia Vision and Shifamed’s other portfolio companies.

Please submit your resume to hr@shifamed.com.

Note: Principals only. No third-party referrals will be accepted without prior approval by Shifamed. As a general practice, Shifamed does not accept unsolicited resumes or placement information from any individual or agency that supplies candidates for a fee.

News

Atia Vision Closes Second Tranche of $20M in Series D Financing

CAMPBELL, CA – May 2, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, announced today initial closing of its committed $20M Series D preferred stock financing. Financing was led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital. The financing will be used to advance Atia Vision’s clinical efforts.

Read More >

Atia Vision Announces Upcoming Presentations Highlighting Modular Presbyopia-Correcting Intraocular Lens Technology

CAMPBELL, CA – September 11, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a novel modular presbyopiacorrecting intraocular lens (IOL), today announced its technology will be featured in presentations at two ophthalmology conferences this week in Paris, France.

Read More >

Atia Vision, A Shifamed Portfolio Company, Closes $20M in Series D Financing

CAMPBELL, CA – May 2, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, announced today initial closing of its committed $20M Series D preferred stock financing. Financing was led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital. The financing will be used to advance Atia Vision’s clinical efforts.

Read More >

Contact

Atia Vision, Inc.
550 Division Street
Campbell, CA 95008
info@atiavision.com

  1. World Health Organization, Visual Impairment and Blindness October 2017.
  2. YourSightMatters.com
  3. Market Scope 2017

Clinical Need

Cataracts are a loss of vision due to lens clouding.

If left untreated, cataracts can lead to blindness.

Current treatment options have limitations with visual side effects: glares, halos and artifacts.

Currently no solution mimics the natural ability of the eye to provide a full range of vision, from distance to near.

Solution

Atia Vision Modular Presbyopia Correcting Intraocular Lens (IOL)

Designed for true accommodation, aiming to restore the full range of vision

Seeking the Precision of True Accommodation

Accommodating base that is responsive to the ciliary muscles, simulating the natural mechanism of the eye

Aiming for a No-Compromise Treatment

Dual lens that addresses the needs of each patient and allows for future refractive corrections

Maintaining Clinical Workflow

Clinician control throughout a familiar conventional cataract procedure

See How It Works

Watch the video to learn more about the Atia Vision Modular Presbyopia Correcting IOL

Company

Atia Vision is a portfolio company of Shifamed, LLC, a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.

The team at Atia Vision is committed to improving patient outcomes by developing a safe and controllable presbyopia correcting IOL that aims to restore the full range of functional vision in cataract patients, the largest segment of the ophthalmology market.3

Management Team

Mariam Maghribi

President & CEO

David Voris

Chief Financial Officer

John Scholl

Vice President, Product Development

Debbie White

Senior Vice President, Human Resources

Robert Edesess

Vice President, Intellectual Property

Melissa Guerrero

Director of Quality Assurance

Helene Lamielle

Clinical & Regulatory Consultant

Board of Directors

Amr Salahieh

Atia Vision Chairman, President & CEO, Shifamed

Mariam Maghribi

President & CEO, Atia Vision

Claudio Argento

Chief Technology Officer, Atia Vision

Bihua Chen

Founder & CEO, Cormorant Assent Management

Henry Chen

Founder & Managing Partner, Delos Capital

Casey Gordon

Head of Private Investments, The Capital Partnership

Interested in joining the Atia Vision team?

Click here to see open positions with Atia Vision and Shifamed’s other portfolio companies.

Please submit your resume to hr@shifamed.com.

Note: Principals only. No third-party referrals will be accepted without prior approval by Shifamed. As a general practice, Shifamed does not accept unsolicited resumes or placement information from any individual or agency that supplies candidates for a fee.

News

Atia Vision Closes Second Tranche of $20M in Series D Financing

CAMPBELL, CA – May 2, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, announced today initial closing of its committed $20M Series D preferred stock financing. Financing was led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital. The financing will be used to advance Atia Vision’s clinical efforts.

Read More >

Atia Vision Announces Upcoming Presentations Highlighting Modular Presbyopia-Correcting Intraocular Lens Technology

CAMPBELL, CA – September 11, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a novel modular presbyopiacorrecting intraocular lens (IOL), today announced its technology will be featured in presentations at two ophthalmology conferences this week in Paris, France.

Read More >

Atia Vision, A Shifamed Portfolio Company, Closes $20M in Series D Financing

CAMPBELL, CA – May 2, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, announced today initial closing of its committed $20M Series D preferred stock financing. Financing was led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital. The financing will be used to advance Atia Vision’s clinical efforts.

Read More >

Contact

Atia Vision, Inc.

550 Division Street

Campbell, CA 95008

info@atiavision.com

  1. World Health Organization, Visual Impairment and Blindness October 2017.
  2. YourSightMatters.com
  3. Market Scope 2017